Teva Pays Out $225m To Settle Criminal Price-Fixing Charges In US
Glenmark Also Settles For $30m; Both Firms Must Divest Pravastatin As Part Of DoJ Deals
• By David Wallace
Generate a summary of this article
Listen to this article
Teva has agreed to pay a $225m fine, as well as donating $50m worth of medicines and divesting a product from its portfolio, as part of a settlement with the US Department of Justice over criminal price-fixing charges. Meanwhile, Glenmark has also struck a $30m settlement with the DoJ.
Teva has agreed to pay a $225m fine to settle price-fixing charges • Source: Shutterstock
A major legal overhang for Teva looks to have been removed after the Israeli generics giant announced that it had struck a deal with the US Department of Justice to settle longstanding criminal charges over generic price-fixing.
The charges – brought against Teva in 2020 (see sidebar for full details) – included allegations that the firm conspired...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.
The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.
Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.